Stock IMNN IMUNON, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Imunon, Inc.

Equities

IMNN

US15117N6022

Market Closed - Nasdaq
Other stock markets
 21:00:00 07/05/2024 BST 		5-day change 1st Jan Change
1.28 USD -2.29% Intraday chart for Imunon, Inc. -2.29% +88.24%
04-18 Imunon Receives FDA Approval to Start Phase 1 Trial of COVID-19 Booster Vaccine MT
04-18 Imunon Shares Rise 8% After Clearance to Start Phase 1 Trial for Covid-19 Booster Vaccine DJ

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
IMUNON to Hold First Quarter 2024 Financial Results and Business Update Conference Call on Monday, May 13, 2024
AQ
IMUNON’s IND Application Cleared to Begin Human Testing of IMNN-101
AQ
IMUNON Reports Compliance with Nasdaq Listing Requirements
AQ
IMUNON Reports 2023 Financial Results and Provides Business Update
AQ
IMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating Losses
AQ
IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024
AQ
IMUNON Files IND Application to Begin Human Testing of IMNN-101
AQ
IMUNON Announces Leadership Change
AQ
Independent Lab Confirms Immunogenicity and Protection with IMUNON’s IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5
AQ
Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer
AQ
IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal Vaccine
AQ
IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
IMUNON’s VP of R&D to Present at the Vaccines Summit-2023
AQ
IMUNON Reports Third Quarter 2023 Financial Results and Provides a Business Update
AQ
IMUNON to Hold Third Quarter 2023 Financial Results and Business Update Conference Call on Tuesday, November 14, 2023
AQ
IMUNON’s Chief Science Officer to Present at the 3rd International Vaccines Congress
AQ
IMUNON CEO Dr. Corinne Le Goff to Participate in a Panel Discussion on Pandemic Preparedness at the United Nations
AQ
IMUNON Announces First Patient enrolled in Phase 1/2 Clinical Trial of IMNN-001 in Combination with bevacizumab in Advanced Ovarian Cancer
AQ
IMUNON Appoints Dr. Patrick Ott to its Scientific Advisory Board
AQ
IMUNON Reports Interim Progression-Free Survival and Overall Survival Data in Phase 1/2 OVATION 2 Study in Advanced Ovarian Cancer
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IMNN Stock
  4. News Imunon, Inc.
  5. Press Releases